Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

NIAID News Release

HIV Vaccine Research Is "Best Hope" for Controlling AIDS Pandemic

Fifth Annual HIV Vaccine Awareness Day to Highlight Progress, Goals for Future

May 16, 2002

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

May 18th marks the Fifth Annual HIV Vaccine Awareness Day, which highlights research advances and the challenges of the HIV/AIDS pandemic, and underscores why developing preventive HIV vaccines offers the best hope for controlling the AIDS pandemic. Thousands of volunteers worldwide who have participated in studies to test candidate HIV vaccines will be recognized. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health has been supporting HIV vaccine studies since 1987.

"HIV vaccine research is our best hope, along with other prevention efforts, to slow the spread of HIV," says NIAID Director Anthony S. Fauci, M.D. "May 18th provides us with an opportunity to recognize the researchers, community educators, and thousands of volunteers around the world who have been involved in the quest for an HIV vaccine."

Increased federal funding has expanded the HIV vaccine pipeline by allowing for more exploration of various vaccine strategies. During the past 5 years, 6 potential HIV vaccines were tested in 12 small-scale clinical trials conducted both here and around the world. Over the next 2 years, more than a dozen potential vaccines are expected to be ready for testing requiring more than 20 clinical trials of various sizes. This investment in vaccine research has made the discovery of an effective HIV vaccine more possible today than ever before.

"The public needs to understand that AIDS is not under control," says Margaret (Peggy) I. Johnston, Ph.D., associate director for HIV/AIDS vaccines, NIAID. "HIV continues to spread unabated in many parts of the world. What we need is to stop that spread, and the best hope to do that is through a safe and effective preventive HIV vaccine. We definitely need public support and particularly the cooperation of volunteers in our clinical research if we are going to achieve that goal."

Advertisement
More than 60 medical research centers around the country have recruited thousands of volunteers to test dozens of potential vaccines. NIAID is currently sponsoring multiple clinical trials of HIV vaccine candidates with the support of its global HIV Vaccine Trials Network (HVTN). These vaccine trials will one day require tens of thousands of additional volunteers. Currently, more than 12,000 men and women worldwide have come forward as volunteers for HIV vaccine research.

"These trials will lead to a vaccine, perhaps not in a year or two or even three years, but we will get there," says Dr. Fauci. "When we do, we will have the ability to significantly control the spread of HIV in the same way we have succeeded against smallpox, polio and measles. Without these trials, and the support of thousands of volunteers who will participate, HIV will continue to devastate communities throughout the United States and the world."

Gary J. Nabel, M.D., Ph.D., director of the Dale and Betty Bumpers Vaccine Research Center in NIAID (http://www.niaid.nih.gov/vrc/), hopes HIV Vaccine Awareness Day will prompt the public to "learn more about HIV vaccine research -- the steps it has taken to get where we are today and the promise of tomorrow." He says, "The challenge is to turn HIV/AIDS into a disease of the past."

Every day, an estimated 14,000 people worldwide become infected with HIV, according to the Joint United Nations Programme on HIV/AIDS. More than half of new infections occur in young people under age 25. Approximately 8 percent of the 37.2 million adults living with HIV/AIDS worldwide are women, while 2.7 million of the world's children younger than 15 years old live with the disease.

HIV Vaccine Awareness Day activities will be held throughout the United States and at several international sites. This year's events emphasize education and outreach by the research sites, include media events, tours of research facilities, lectures and receptions to honor volunteers. For specific information about events in specific areas, contact:

Baltimore, MD
Johns Hopkins University
Theron Scott: (410) 614-6619

University of Maryland, Baltimore
Sandra Wearins: (410) 706-1290

Birmingham, AL
University of Alabama at Birmingham
Leslie Cooper: (205) 975-2839

Boston, MA
Brigham and Women's Hospital
Fenway Community Health
Angela Wilcox: (617) 927-6352

Durban, South Africa
Medical Research Center
Pumi Yeni: 27-31-203-4828

Gaborone, Botswana
Princess Marina Hospital
Rupert Hambria: (267) 393-1137

Nashville, TN
Vanderbilt University
Susan Montgomery: (615) 322-0873

New York, NY
Project Achieve/New York Blood Center and Columbia University sites
Denise Goodman: (212) 388-0008

Port-au-Prince, Haiti
Cornell-GHESKIO
Dr. Mireille Peck: 509-222-00-31

Providence, RI
Miriam Hospital
Stephanie Howie: (401) 793-4714

Rochester, NY
University of Rochester
Patrick Fisher: (585) 275-0459

San Francisco, CA
San Francisco Department of Public Health
Meredith Broome: (415) 554-9078

Seattle, WA
Fred Hutchinson Cancer Research Center/University of Washington
Dennis Torres: (206) 521-5812

St. Louis, MO
Saint Louis University
Tim Lynch: (314) 268-5448

Washington, DC
Johns Hopkins University
Theron Scott: (410) 614-6619

More information on HIV Vaccine Research and HIV Vaccine Awareness Day is available at http://www.niaid.nih.gov/hivvaccines, the HIV Vaccine Trials Network at http://www.hvtn.org and the NIAID Vaccine Research Center at http://www.niaid.nih.gov/vrc/.

TV Media: Video news release and B-roll available with sound bites from Dr. Anthony S. Fauci, NIAID director; Dr. Peggy I. Johnston, associate director for HIV/AIDS vaccines, NIAID; Dr. Gary J. Nabel, director of the Dale and Betty Bumpers Vaccine Research Center, NIAID; Dr. Chad Womack, researcher, VRC, NIAID; and Sandra Wearins, vaccine trial volunteer. Also included are laboratory shots and exterior views of the Dale and Betty Bumpers Vaccine Research Center. A Spanish version of the VNR features Dr. Jorge Flores, chief of Vaccine Clinical Research Branch in NIAID's Division of AIDS. For information on a satellite feed, call 1-800-920-6397.

Radio Broadcasters: Sound bites are available by calling the NIH Radio News Service at 1-800-MED DIAL (1-800-633-3425).

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

 
See Also
More News and Analysis on Vaccines for HIV Prevention

Tools
 

Advertisement